Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288]

S. Loibl, M. Untch, N. Burchardi, J. Huober, B.V. Sinn,J.-U. Blohmer, E.-M. Grischke, J. Furlanetto, H. Tesch, C. Hanusch, K. Engels, M. Rezai, C. Jackisch,W.D. Schmitt,G. von Minckwitz, J. Thomalla,S. Kümmel, B. Rautenberg,P.A. Fasching,K. Weber

Annals of Oncology(2022)

引用 1|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要